Read + Share
Altundag K. Re: Overall survival with palbociclib plus endocrine therapy versus capecitabine
in postmenopausal patients with hormone receptor-positive, HER2-negative
metastatic breast cancer in the PEARL study: Higher visceral tumour burden and
weak estrogen rece Eur J Cancer 2022;171:43.
PMID: 35704973
|
 |
|
